Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Government agencies communicate via .gov.sg websites (e.g. go.gov.sg/open). Trusted websites
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

Agency for Care Effectiveness
Published

Gout — achieving the management goal ACG

Condition

Endocrine and metabolic

Musculoskeletal

Guidance type

ACG

14 December 2023

Published on 20 Dec 2019
Last Updated on 14 Dec 2023

This ACE Clinical Guideline (ACG) highlights the pharmacological and non-pharmacological aspects of long-term management of gout, with a focus on urate-lowering therapy (ULT), prophylaxis, and acute flare treatment. Specifically, the ACG offers evidence-based recommendations on initiation of ULT for patients who meet the treatment criteria, provision of prophylaxis during the initial period of ULT, monitoring and risk mitigation for severe cutaneous adverse reactions (SCARs), as well as management of acute flares. Two patient education aids are included to assist discussions between healthcare professionals and patients.

Download the ACG

Gout – achieving the management goal (Dec 2023) [PDF]

Or click the link below for the web version

 Gout – achieving the management goal (Dec 2023) [WEB]

Registered doctors, pharmacists and nurses may claim 1 Continuing Medical Education (CME)/Continuing Professional Education (CPE) point under category 3A/ category V-B for reading each ACG.

ACG recommendations

  1. Initiate urate-lowering therapy (ULT) for patients who meet the ULT treatment criteria, starting at a low dose and slowly titrating upwards as needed.

  2. Provide prophylaxis with colchicine; if colchicine is not suitable, consider a low-dose oral nonsteroidal anti-inflammatory drug (NSAID), or a low-dose oral corticosteroid if NSAIDs are not suitable.

  3. Mitigate the risk of developing severe cutaneous adverse reactions (SCARs) and provide counselling on SCAR monitoring for patients on allopurinol or febuxostat.

  4. Manage acute flares as soon as possible, including treatment with colchicine, NSAIDs, or corticosteroids.

ACG references

Gout – achieving the management goal references (Dec 2023) [PDF]

Feedback

Click here to give us feedback on this ACG.

Related ACGs
Back to top